Identifying TRK Fusions in Head and Neck Cancer

Slides:



Advertisements
Similar presentations
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Advertisements

The Nurse View: Management of Pancreatic Cancer
State of the Art in BRCA-Mutated Ovarian Cancer
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Evolving Paradigms in Recurrent/Metastatic SCCHN
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Challenges in RAS Wild-Type mCRC
An Introduction to DNA Damage Repair in Cancer: Beyond PARP
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Advanced NSCLC Without Actionable Mutations
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Thrombosis, Cancer, and NOACs
New Patient Journeys in Non-small cell lung cancer
Applying New Data in Practice:
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.
Introduction to Checkpoint Inhibitors
The Genomics of Cancer and Molecular Testing:
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Extended Half-life Factor Products in the Management of Hemophilia
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Optimizing Outcomes in the Management of GIST
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
PARP Inhibitors and Cancer: What Do You Need to Know?
Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Tailoring Hemophilia Prophylaxis Therapy
Counseling Patients About Germline BRCA Mutations
CDK4/6 Inhibitors in Practice
Clinical Updates in RA: New Developments and Insights From Washington
Managing gBRCA-Positive Metastatic Breast Cancer
Treating mRCC After Initial Antiangiogenic Therapy:
Treatment of HR+ Breast Cancer: A Clinical Update
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
VTE in Cancer.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Using Heart Rate as a Biomarker in Clinical Practice.
Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.
Updates in Cardiovascular Medicine
T2DM Management.
Maintenance Therapy in Advanced Ovarian Cancer
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Cancer-Associated Thrombosis
Extended Half-life Factor Products in the Management of Hemophilia
Progress of the NSCLC Revolution
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Emerging Targets for the Diagnosis of Cancer
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Optimizing Joint Health in Hemophilia
Practical Guidance on the Management of Pan-Negative NSCLC
Add-On Therapy to Insulin in T1DM Management
How Can Precision Medicine in Oncology Refine Best Treatment Approach?
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
When Is Intrathecal Drug Delivery Appropriate?
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
CDK4/6 Inhibitors.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
A Closer Look.
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
ROS1 Translocations and NSCLC
Current Status of Biomarkers for Immune Checkpoint Inhibitors
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.
Updates in Best Practices in Non-Small Cell Lung Cancer
The Power of As-Treated Analyses
Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.
The Challenge of Insulin Titration
Presentation transcript:

Identifying TRK Fusions in Head and Neck Cancer

Introduction

Overview of NTRK

NTRK Fusions

Frequency of NTRK Fusions

NTRK Fusions in Salivary Gland and Thyroid Cancers

Identifying Appropriate Patients for NTRK Testing

Identifying Appropriate Patients for NTRK Testing, cont

Challenges in Identifying Secretory Histology in Salivary Gland Cancer

Optimal Timing for NTRK Testing

NTRK Fusions vs Point Mutations

Testing for TRK Fusions

NTRK Inhibitors

Overview of Larotrectinib Clinical Trials

Larotrectinib in Subset of Patients With Salivary Gland and Thyroid Cancers

Larotrectinib in Subset of Patients With Salivary Gland and Thyroid Cancers (cont)

Larotrectinib Clinical Trials: 2019 Update

Select Larotrectinib TRAEs in Clinical Trials

Overview of Entrectinib Clinical Trials

Resistance to TRK Inhibitors

LOXO-195 in Larotrectinib-Resistant Patients

Repotrectinib in Larotrectinib-Resistant Patients

Unanswered Questions

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.